We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Rectangle Image
News

Dr Kevin Doyle Appointed Head of Chemistry at Domainex

Rectangle Image
News

Dr Kevin Doyle Appointed Head of Chemistry at Domainex

Dr Kevin Doyle has been appointed Head of Chemistry with immediate effect. Credit: Domainex Ltd
Read time:
 

Domainex Ltd, a privately-owned drug discovery services company, is pleased to announce that Dr Kevin Doyle has been appointed Head of Chemistry with immediate effect. His appointment strengthens the expanding team of international scientists at its research facilities on Chesterford Research Park, based in Cambridge, UK, which has grown by more than 50% in the past 18 months.

‘I am delighted to join the team at Domainex,’ said Dr Doyle. ‘Domainex is clearly a rapidly-growing CRO and has been ‘one to watch’ for some time now. The opportunity to be a part of it, and to help shape the future of its medicinal chemistry was one that I could not miss. I am looking forward to working alongside the talented scientists there and to meeting and supporting the impressive list of clients from all around the world.'

Kevin Doyle is a medicinal chemist with more than 20 years’ experience in the pharmaceutical industry. He joins Domainex from Charles River Laboratories where he led numerous integrated drug discovery projects with international pharmaceutical and biotech companies, as well as with patient foundations. In previous roles, he worked at BASF and OSI Pharmaceuticals

‘We are delighted to welcome Kevin to Domainex,’ commented Dr Tom Mander, COO of the company. ‘His wealth of experience within the contract drug discovery research environment will be invaluable in helping Domainex to strengthen our integrated drug discovery platform further. Kevin will play a strategic role in attracting more pharmaceutical and biotechnology companies to Domainex, developing innovative new services and helping to extend our reputation for delivering innovative new medicinal therapies for our clients.’

This article has been republished from materials provided by Domainex. Note: material may have been edited for length and content. For further information, please contact the cited source.

Advertisement